CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Long-term 5HT3 Antagonist Use for Tinnitus: Clinical Evidence and Guidelines

Last updated: June 23, 2014
Project Number: RA0682-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

  1. What are the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of tinnitus?
  2. What are the evidence-based guidelines for the use of 5HT3 antagonists for the treatment of tinnitus?

Key Message

One randomized controlled trial was identified regarding the clinical benefits and harms of long term (>5 day) 5HT3 antagonist use for the treatment of tinnitus.